Totus Medicines, billed as 'a company revolutionizing small-molecule drug discovery and development using covalent DNA-encoded libraries and AI tools', has announced a multi-target research collaboration with Eli Lilly aimed at discovering small-molecule drug candidates against undisclosed targets.

Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to generate high-quality covalent compounds against Eli Lilly's targets.

Thereafter, Lilly and Totus will have the option to exclusively pursue preclinical and clinical development and commercialization of the compounds identified during the collaboration, and to receive milestone payments.



Copyright (c) 2024 CercleFinance.com. All rights reserved.